|
Gadolinium MRI Contrast Agent
Nephrogenic Systemic Fibrosis (NSF) | Nephrogenic Fibrosing Dermopathy (NFD)
Gadolinium is an FDA-approved contrast agent for magnetic resonance imaging (MRI). Gadolinium is also called gadolinium-DPTA and gadodiamide, and it goes by various brand names. Gadolinium is non-radioactive and resembles plain water.
FDA REPORTS
FDA reports have identified a possible link between Nephrogenic Systemic Fibrosis (NSF) and/or Nephrogenic Fibrosing Dermopathy (NFD) and exposure to gadolinium containing contrast agents used at high doses for a procedure called Magnetic Resonance Angiography (MRA).
In particular, the FDA black box warning - updated on 5/23/2007 - reports that patients with severe kidney insufficiency who receive gadolinium-based agents are at risk for developing a debilitating, and a potentially fatal disease known as nephrogenic systemic fibrosis (NSF).
For more on gadolinium contrast agent cases, please follow this link.
Please navigate to the links below to find more information on a variety of topics and what you can do to protect your legal rights or contact us.
|
